Daily non-political popular news in brief.

Study finds HIV protease inhibitor drugs may adversely affect the scaffolding of the cell nucleus

UCLA scientists, along with collaborators from Purdue University, have demonstrated that HIV protease inhibitors -- crucial drugs for HIV treatment -- block a cellular enzyme important for generating the structural scaffolding for the cell nucleus. The findings may offer insight into the side effects of HIV protease inhibitors.

Read more »

Keywords: study, hiv, protease, inhibitor, drugs, adversely, affect, scaffolding, cell, nucleus, drug, nucleu

« Previous | Next »

Similar news on "Study finds HIV protease inhibitor drugs may adversely affect the scaffolding of the cell nucleus":

1. Discovery of an HIV inhibitor in human blood points to new drug class
   04-19-2007 · EurekAlert!
   A new study has pinpointed a natural ingredient of human blood that effectively blocks HIV-1, the virus predominantly responsible for human AIDS, from infecting immune cells and multiplying. The virus blocker might play a role in the progression of HIV to full-blown AIDS and -- because it works in a different way than existing antiretroviral inhibitors -- could lead to the development of another class of drugs in the fight against the pandemic disease.
   Similar news · Read more »
   
2. Drug cocktail stops brain damage caused by HIV
   10-08-2007 · EurekAlert!
   A combination of drugs widely used to treat infections caused by HIV appears to stop brain damage caused by the virus as well, according to a study published in the Oct. 9, 2007, issue of Neurology, the medical journal of the American Academy of Neurology.
   Similar news · Read more »
   
3. Socioeconomic position associated with effectiveness of HIV drugs
   09-07-2007 · EurekAlert!
   Socioeconomic position is a determinant of antiretroviral treatment effectiveness during initial therapy for HIV-1 infection. The effect was found even among subjects with high rates of drug adherence, according to a study published in the Aug. 1 issue of the Journal of Psychosomatic Research.
   Similar news · Read more »
   
4. 2 drugs work better together than either alone against kidney cancer
   07-30-2007 · EurekAlert!
   A combination of two drugs works better than either drug alone for patients with renal cell carcinoma, the most common form of kidney cancer, according to a pilot study led by Duke University Comprehensive Cancer Center researchers.
   Similar news · Read more »
   
5. Study suggests brain tumors need treatment with multiple 'targeted' drugs
   09-13-2007 · EurekAlert!
   Researchers at Dana-Farber Cancer Institute have shown that several, rather than just one, cell-growth switches are simultaneously overactive in many brain tumors and other solid tumors, explaining why treatment with just a single "targeted" switch-blocking drug often yields disappointing results.
   Similar news · Read more »
   
6. Protein inhibitor tangles with Alzheimer's disease
   02-15-2007 · EurekAlert!
   A hallmark of Alzheimer's disease (AD) is the abnormal accumulation of phosphorylated forms of a protein known as tau. In a new study, Mayo Clinic researchers have now shown in mice that a drug that inhibits the function of the protein Hsp90 (EC102) reduces the amount of phosphorylated tau in the brain. Unlike many drugs, EC102 is able to cross the blood-brain barrier, making it a highly promising therapeutic candidate for AD.
   Similar news · Read more »
   
7. European approval of HIV drug darunavir will provide a potent new option with Fuzeon
   02-16-2007 · EurekAlert!
   Today's approval of the new protease inhibitor (PI) darunavir (boosted with ritonivir) provides physicians with the opportunity to build a potent new treatment combination with the fusion inhibitor, Fuzeon.
   Similar news · Read more »
   
8. Widely used hepatitis B drug spurs HIV drug resistance
   02-28-2007 · EurekAlert!
   A Johns Hopkins study has proven false established medical practice that an antiretroviral drug widely used to treat hepatitis B liver infections was safe to use on its own in patients co-infected with HIV. Their findings demonstrate that treatment with entecavir leads to cross-resistance to other antiviral drugs used to treat the AIDS virus.
   Similar news · Read more »
   
9. Drugs users are increasingly more cautious with needles
   05-14-2007 · EurekAlert!
   Even though HIV can be well treated these days, drug users are still more cautious about using needles than they used to be. That is the conclusion of Colette Smit following her study into 25 years of HIV in the Netherlands.
   Similar news · Read more »
   
10. New study indicates Invirase results in similar levels of viral suppression to lopinavir
    11-13-2006 · EurekAlert!
    Promising head to head results presented today indicate that the boosted protease inhibitor (PI/r) Invirase 500/r appears to achieve similar levels of viral suppression compared to the most commonly used PI, lopinavir/r, while significantly fewer patients developed elevated lipids. These results are from a planned 24 week interim analysis of 150 patients from the Gemini study presented at the HIV-8 congress in Glasgow.1
    Similar news · Read more »